Immunology/inflammation companies
57 listed immunology/inflammation companies, largest first, with lead program and the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| AbbVie Inc. | ABBV | Rinvoq (upadacitinib) | multiple immune-mediated diseases (new submissions: non-segmental vitiligo, severe alopecia areata) | — |
| Sanofi | SNY | Dupixent (dupilumab; marketed portfolio) | Atopic dermatitis and other type 2 inflammatory diseases | 2026 — Start of Phase 3 in asthma |
| Argenx SE | ARGX | VYVGART | generalized myasthenia gravis, CIDP, ITP | December 2026 — Phase 3 MMN data for empasiprubart are expected in December 2026. |
| Roivant Sciences Ltd. | ROIV | brepocitinib | dermatomyositis | H2 2026 — Phase 2 data |
| Spyre Therapeutics, Inc. | SYRE | SKYLINE (SPY001, SPY002, SPY003 and combinations) | Ulcerative colitis | Q4 2026 — SKYWAY PsA and axSpA sub-study topline data expected 4Q 2026; SPY003 SKYLINE Part A UC data September 2026. |
| Kymera Therapeutics, Inc. | KYMR | KT-621 (STAT6 degrader) | Atopic dermatitis (BROADEN2) and asthma (BREADTH) | — |
| Protagonist Therapeutics, Inc | PTGX | PN-881 | Immune-mediated skin diseases, plaque psoriasis (oral IL-17 antagonist peptide) | Q1 2027 — Initiation of Phase 2b psoriasis program |
| Kiniksa Pharmaceuticals International, plc | KNSA | ARCALYST (rilonacept) | Recurrent pericarditis | 2026 — Enter Phase 1 |
| Immunovant, Inc. | IMVT | IMVT-1402 (imeroprubart) | Graves' disease; D2T rheumatoid arthritis; myasthenia gravis; CIDP; Sjogren's disease | H2 2026 — Further program updates |
| Dianthus Therapeutics, Inc. | DNTH | claseprubart (DNTH103) | CIDP (CAPTIVATE) and generalized myasthenia gravis (EMERGE) | December 2026 — MoMeNtum Phase 2 topline |
| Adma Biologics, Inc. | ADMA | ASCENIV (Immune Globulin Intravenous, Human - slra 10% Liquid) | Primary humoral immunodeficiency (PI/PIDD) | 2026 — Submission of pre-IND package to FDA |
| Celldex Therapeutics, Inc. | CLDX | barzolvolimab (CDX-0159) | chronic spontaneous urticaria (CSU) | 2027 — BLA filing (assuming positive Phase 3) |
| Aurinia Pharmaceuticals Inc. | AUPH | LUPKYNIS (voclosporin) | active lupus nephritis (adults) | — |
| Lakefront Biotherapeutics | LKFT | Gamgertamig (OM336) | Autoimmune cytopenias (ITP, AIHA) and seropositive autoimmune diseases (myositis, Sjogren's, pemphigus) | 2027 — Expected entry into registrational studies (Gilead-led) |
| Biocryst Pharmaceuticals Inc | BCRX | ORLADEYO (berotralstat) | prevention of hereditary angioedema (HAE) attacks | — |
| First Tracks Biotherapeutics, Inc. | TRAX | Rosnilimab | rheumatoid arthritis | Q1 2027 — Cohort 2 enrollment completing imminently; topline Q1 2027. |
| Alvotech | ALVO | SIMLANDI (adalimumab-ryvk) | Humira (adalimumab) biosimilar; autoimmune disease | — |
| Zenas BioPharma, Inc. | ZBIO | obexelimab | IgG4-related disease | Q4 2026 — Topline results from the Phase 2 SunStone trial in Systemic Lupus Erythematosus expected in 4Q 2026. |
| ANI Pharmaceuticals Inc | ANIP | Purified Cortrophin Gel (repository corticotropin injection) | chronic autoimmune disorders incl. acute exacerbations of MS and RA; nephrotic syndrome; acute gouty arthritis flares | — |
| Nektar Therapeutics | NKTR | rezpegaldesleukin (REZPEG) | moderate-to-severe atopic dermatitis | Q1 2027 — Initiate global registrational ZENITH-AA-1 trial in alopecia areata |
| Vor Biopharma Inc. | VOR | Telitacicept (licensed from RemeGen, ex-Greater China rights) | Generalized myasthenia gravis (global Phase 3); Sjögren's disease (global Phase 3) | — |
| MoonLake Immunotherapeutics | MLTX | sonelokimab (SLK, M1095) | moderate-to-severe hidradenitis suppurativa (HS) | H2 2026 — Final topline results |
| Odyssey Therapeutics, Inc. | ODTX | OD-001 | ulcerative colitis | H2 2026 — CTA filing outside the US |
| Jade Biosciences, Inc. | JBIO | JADE101 | IgA nephropathy (IgAN) | H1 2027 — Initiate registrational Phase 3 in IgAN |
| Monte Rosa Therapeutics, Inc. | GLUE | MRT-8102 (NEK7 molecular glue degrader) | Inflammatory diseases (NEK7/NLRP3-driven) | — |
| Alumis Inc. | ALMS | envudeucitinib (envu, formerly ESK-001) | moderate-to-severe plaque psoriasis | H1 2027 — Initiate Phase 2 biomarker trial in Parkinson's disease |
| Pharming Group N.V. | PHAR | Joenja (leniolisib) | Activated PI3K delta syndrome (APDS) | November 2026 — Phase II topline results |
| Attovia Therapeutics, Inc. | ATTO | ATTO-1310 | Chronic pruritus / high-itch atopic dermatitis (also CPUO, cholestatic pruritus, CKD-aP planned) | H1 2027 — Initiate Phase 2 clinical trial |
| DBV Technologies S.A. | DBVT | Viaskin Peanut patch | Peanut allergy in children (4 through 7 years; also ages 1 through 3) | — |
| Aclaris Therapeutics, Inc. | ACRS | Bosakitug (ATI-045) | Moderate to severe atopic dermatitis | Q4 2026 — Phase 2 atopic dermatitis top-line data |
| Shattuck Labs, Inc. | STTK | SL-325 | Inflammatory bowel disease (Crohn's disease Phase 2b planned) | H2 2026 — Additional preclinical data including NHP toxicology |
| Aquestive Therapeutics, Inc. | AQST | Anaphylm (dibutepinephrine) sublingual film | Severe allergic reactions including anaphylaxis | H2 2026 — Additional preclinical and clinical studies |
| ARS Pharmaceuticals, Inc. | SPRY | neffy (intranasal epinephrine) | emergency treatment of Type I allergic reactions including anaphylaxis | 2026 — Canadian commercial launch by partner ALK |
| TRex Bio, Inc. | TRXB | TRB-061 | Moderate-to-severe atopic dermatitis (also exploring alopecia areata and other autoimmune and inflammatory diseases) | H2 2026 — Lilly intends to start Phase 2a trial in lupus with cutaneous involvement |
| Avalo Therapeutics, Inc. | AVTX | abdakibart (AVTX-009) | hidradenitis suppurativa | — |
| Zura Bio Ltd | ZURA | tibulizumab (ZB-106) | Hidradenitis suppurativa (TibuSHIELD) and early diffuse cutaneous systemic sclerosis (TibuSURE) | Q4 2026 — TibuSHIELD Phase 2 topline results |
| Artiva Biotherapeutics, Inc. | ARTV | AlloNK (AB-101) plus rituximab | Refractory rheumatoid arthritis (lead); also Sjögren’s disease, systemic sclerosis, idiopathic inflammatory myopathies | H2 2026 — Initiation of registrational Phase 3 trial in refractory RA |
| Century Therapeutics, Inc. | IPSC | CNTY-101 (iPSC-derived allogeneic CD19 CAR-iNK) | B-cell malignancies / autoimmune (CARAMEL investigator-sponsored Phase 1/2) | Q4 2026 — IND submission |
| SAB Biotherapeutics, Inc. | SABS | SAB-142 (fully human anti-thymocyte globulin, Tc-Bovine derived) | Stage 3 autoimmune type 1 diabetes (new or recent onset) | — |
| Q32 Bio Inc. | QTTB | bempikibart (ADX-914) | Alopecia areata | — |
| Fate Therapeutics Inc | FATE | FT819 (iPSC-derived CAR T-cell) | systemic lupus erythematosus (with and without lupus nephritis) | — |
| Cabaletta Bio, Inc. | CABA | rese-cel (resecabtagene autoleucel, CABA-201) | Autoimmune disease; lead registrational cohort in dermatomyositis / anti-synthetase syndrome (myositis) | June 2027 — BLA-enabling topline data from registrational cohort |
| InflaRx N.V. | IFRX | izicopan (oral C5aR inhibitor) | ANCA-associated vasculitis (AAV) and other complement-mediated renal disease; HS and CSU Phase 2a completed | July 1, 2027 — US EUA termination becomes effective |
| Eledon Pharmaceuticals, Inc. | ELDN | tegoprubart | Prevention of allograft rejection in kidney transplantation | H2 2026 — Initiation of Phase 3 clinical development |
| Evommune, Inc. | EVMN | EVO756 | Moderate-to-severe atopic dermatitis | Q2 2027 — Phase 2b commencement |
| KORU Medical Systems, Inc. | KRMD | FREEDOM Infusion System | Subcutaneous immunoglobulin (SCIg) and other large-volume subcutaneous infusion (PIDD, CIDP) | — |
| Cue Biopharma, Inc. | CUE | CUE-221 | allergic diseases (chronic spontaneous urticaria Phase 2; food allergy planned) | 2026 — IND submission and Phase 1 start |
| Nkarta, Inc. | NKTX | NKX019 | Autoimmune diseases (lupus nephritis, primary membranous nephropathy, systemic sclerosis, myositis, ANCA-associated vasculitis, rheumatoid arthritis) | — |
| Spero Therapeutics, Inc. | SPRO | SP001 | IgG4-related disease | Q2 2027 — Advance into Phase 2 trial in IgG4-RD patients (subject to FDA IND clearance) |
| ImageneBio, Inc. | IMA | IMG-007 (olevaprubart) | Moderate-to-severe atopic dermatitis | 2026 — Alopecia areata Phase 2 initiation |
| Nasus Pharma Ltd | NSRX | NS002 (intranasal epinephrine powder, PBI technology) | emergency treatment of allergic reactions / anaphylaxis (emergency medical conditions) | — |
| Adicet Bio, Inc. | ACET | prula-cel (prulacabtagene leucel, ADI-001) | autoimmune diseases (lupus nephritis, SLE, SSc, AAV, IIM, SPS) | H2 2026 — Potential pivotal program start in LN, subject to regulatory clearance |
| Processa Pharmaceuticals, Inc. | PCSA | VT-7208 | Food allergy, chronic spontaneous urticaria, relapsing multiple sclerosis | H2 2026 — Initiate Phase 2 studies in food allergy and CSU |
| Enlivex Ltd. | ENLV | Allocetra | Moderate-to-severe age-related primary knee osteoarthritis | Q2 2027 — Three-month topline data |
| HCW Biologics Inc. | HCWB | HCW9302 | Alopecia areata (autoimmune) | Q4 2026 — Full Phase 1 human data readout |
| Scinai Immunotherapeutics Ltd. | SCNI | NanoAbs (VHH antibody fragment) pipeline; PC111 (option to acquire) | inflammation and immunology; severe dermatological conditions | — |
| CDT Equity Inc. | CDT | AZD1656 co-crystal (HK-4 glucokinase activator) | inflammatory/autoimmune disorders (repurposing, AI-guided) | — |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.